Literature DB >> 15684299

Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer.

T Berghmans1, A P Meert, B Martin, V Ninane, J P Sculier.   

Abstract

New biological factors have not been extensively studied in stage III nonsmall cell lung cancer (NSCLC). The aim of the present retrospective study was to determine the role of epidermal growth factor receptor (EGF-R) as a prognostic factor in stage III NSCLC, in addition to the stage and other known clinical factors. Clinical characteristics were retrieved from the patients' charts. Membrane immunostaining for EGF-R was evaluated by three independent observers. The Cox multivariate model, including all variables with a p-value of <0.2 in univariate analysis, was used to assess the impact of clinical and biological factors on patients survival. Between January 1987 and July 2002, 99 assessable stage III NSCLC patients were included in the study. A total of 23 patients were positive for EGF-R (squamous 39.6% versus nonsquamous 7.8%). In multivariate analysis, only three factors were statistically significantly associated with survival: performance status, surgery and creatinine. In conclusion, good performance status, surgical resection and creatinine were found to be independent favourable prognostic factors for survival in a retrospective analysis of stage III nonsmall cell lung cancer, while epidermal growth factor receptor was not even in the univariate analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684299     DOI: 10.1183/09031936.05.00060804

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Hisao Imai; Kimihiro Shimizu; Noriko Yanagitani; Noriaki Sunaga; Takeshi Hisada; Osamu Kawashima; Yosuke Kamide; Tamotsu Ishizuka; Yoshikatsu Kanai; Takashi Nakajima; Masatomo Mori
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

3.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

4.  Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Chemo-Radiotherapy: An Institutional Analysis.

Authors:  Amna Sher; Sowmini Medavaram; Barbara Nemesure; Sean Clouston; Roger Keresztes
Journal:  Cancer Manag Res       Date:  2020-08-11       Impact factor: 3.989

5.  Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value.

Authors:  Jian-guo Sun; Yan Wang; Zheng-tang Chen; Wen-lei Zhuo; Bo Zhu; Rong-xia Liao; Shao-xiang Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-02-16

6.  EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.

Authors:  Maria I Toki; Daniel E Carvajal-Hausdorf; Mehmet Altan; Joseph McLaughlin; Brian Henick; Kurt A Schalper; Konstantinos N Syrigos; David L Rimm
Journal:  J Thorac Oncol       Date:  2016-07-20       Impact factor: 15.609

7.  Correlation study and significance of the EGFR expression in serum, lymph nodes and tumor tissue of NSCLC.

Authors:  Yinling Zhuo; Qisen Guo; Pingping Song; Qiong Zhang; Chen Guo; Hongsheng Zeng; Yan Guan; Xiuju Liu; Chenqing Zhao
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

8.  Orai3 is a predictive marker of metastasis and survival in resectable lung adenocarcinoma.

Authors:  Nazim Benzerdjeb; Henri Sevestre; Ahmed Ahidouch; Halima Ouadid-Ahidouch
Journal:  Oncotarget       Date:  2016-12-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.